RPR Seeks FDA Clearance For Drug
Selected Abstract
RPR Seeks FDA Clearance For Drug To Treat Unstable Angina
COLLEGEVILLE, Pa., March 19 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Lovenox(R) (enoxaparin sodium) Injection for the treatment of unstable angina, a key ... March 19, 1997; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
RPR Seeks FDA Clearance For Drug To Treat Unstable Angina
|
